Publications by authors named "A Bastien"
Article Synopsis
- - Mavacamten is a cardiac myosin inhibitor approved by the FDA specifically for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), requiring monitoring for heart failure and low left ventricular ejection fraction (LVEF) as part of a risk management program.
- - Data from the mavacamten REMS database, spanning from April 2022 to February 2024, included over 6,000 patients, revealing that 4.6% experienced a decrease in LVEF to below 50%, while 1.3% required hospitalization for heart failure.
- - A majority of patients remained on the prescribed doses of mavacamten, with significant improvements in heart function observed: 57.
Our understanding of dilated cardiomyopathy (DCM) is evolving as new insights into the underlying pathophysiology become available. Professional organizations and clinical experts are improving definitions of DCM, allowing for more accurate treatment recommendations. This review summarized key published literature describing definitions and/or diagnostic criteria for DCM.
View Article and Find Full Text PDF